RECRUITING

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

Talk to us

Conditions

Lymphoma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.

Official Title

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

Quick Facts

Study Start:2023-10-06
Study Completion:2027-08-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06049134

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Patients who have a history of non-Hodgkin B-cell lymphoma and whose disease has been in remission for at least 1 year.
  2. 2. Patients who received any anti-CD20 therapy at any time during their treatment for B-cell lymphoma.
  3. 3. Patients who are at least 18 years of age.
  4. 4. Patients who can provide consent; no legal authorized representative will be able to provide consent on a patient's behalf.
  1. 1. Patients who have received cellular therapy, including chimeric antigen receptor T-cell therapy or any type of hematopoietic cell transplantation.
  2. 2. Patients who have received PCV or pneumococcal polysaccharide vaccine within 5 years of screening for enrollment.
  3. 3. Patients who are unable to attend follow-up appointments at designated times at MD Anderson.
  4. 4. Any vulnerable population patient ((children, pregnant women, cognitively impaired adults, or prisoners)

Contacts and Locations

Study Contact

Fareed Khawaja, MD
CONTACT
(281) 610-0253
fkhawaja@mdanderson.org

Principal Investigator

Fareed Khawaja, MD
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

M D Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • Fareed Khawaja, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-06
Study Completion Date2027-08-01

Study Record Updates

Study Start Date2023-10-06
Study Completion Date2027-08-01

Terms related to this study

Additional Relevant MeSH Terms

  • Lymphoma